| 纯度 | >80%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SKA1 |
| Uniprot No | Q96BD8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-255aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMASSDLE QLCSHVNEKI GNIKKTLSLR NCGQEPTLKT VLNKIGDEII VINELLNKLE LEIQYQEQTN NSLKELCESL EEDYKDIEHL KENVPSHLPQ VTVTQSCVKG SDLDPEEPIK VEEPEPVKKP PKEQRSIKEM PFITCDEFNG VPSYMKSRLTYNQINDVIKE INKAVISKYK ILHQPKKSMN SVTRNLYHRF IDEETKDTKG RYFIVEADIK EFTTLKADKK FHVLLNILRH CRRLSEVRGGGLTRYVIT |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SKA1重组蛋白的3篇参考文献示例(文献信息为模拟概括，仅供参考)：
1. **标题**：*Structural insights into SKA1 complex assembly and microtubule interaction*
**作者**：Smith A, et al.
**摘要**：通过重组表达人源SKA1蛋白，解析其与微管结合的分子机制，揭示了SKA1复合体在有丝分裂中稳定染色体运动的构效关系。
2. **标题**：*Recombinant SKA1 purification and functional analysis in vitro*
**作者**：Zhang L, et al.
**摘要**：开发了一种高效的大肠杆菌表达系统用于SKA1重组蛋白的纯化，并验证其在体外微管结合实验中的活性，为后续药物筛选提供基础。
3. **标题**：*SKA1 phosphorylation regulates kinetochore localization in mitosis*
**作者**：Wang Y, et al.
**摘要**：利用重组SKA1蛋白研究磷酸化修饰对其在动粒定位的影响，发现特定激酶调控SKA1在细胞分裂中的动态招募过程。
(注：以上文献为示例，实际研究中请通过PubMed或Web of Science检索具体论文。)
The Spindle and Kinetochore Associated Complex Subunit 1 (SKA1) is a critical component of the SKA complex, which plays an essential role in ensuring accurate chromosome segregation during mitosis. This protein complex, composed of SKA1. SKA2. and SKA3. localizes to the outer kinetochore and interacts with microtubules to stabilize their attachment to chromosomes. Proper SKA1 function is vital for maintaining the mitotic checkpoint, a surveillance mechanism that prevents aneuploidy—a hallmark of many cancers and genetic disorders. Dysregulation of SKA1 has been implicated in tumorigenesis, making it a potential therapeutic target.
Recombinant SKA1 protein, produced through genetic engineering in heterologous expression systems (e.g., *E. coli* or mammalian cells), enables researchers to study its structure, interactions, and biochemical properties in vitro. Its recombinant form typically retains native folding and functional domains, allowing for in-depth investigations into kinetochore-microtubule dynamics and mitotic regulation. Structural studies using X-ray crystallography or cryo-EM have revealed SKA1’s role in forming a flexible dimeric structure that facilitates microtubule binding and force transmission during chromosome movement.
Applications of recombinant SKA1 include drug screening for anticancer agents targeting mitosis, mechanistic studies of chromosome mis-segregation, and identifying binding partners within the kinetochore-microtubule interface. Additionally, it serves as a tool for understanding how post-translational modifications (e.g., phosphorylation) regulate its activity. The development of recombinant SKA1 has accelerated research into mitotic errors linked to genomic instability, offering insights for novel cancer therapies. Its high purity and solubility, often enhanced by affinity tags (e.g., His-tag), streamline experimental workflows in both academic and pharmaceutical settings.
×
